Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.76 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | KIT | P10721 | 4/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8338212 | 0.87 | TRPV1 (1.00) | TRPV1KDM4EMAPTKIT | |
| SCHEMBL8338144 | 0.84 | TRPV1 (1.00) | TRPV1MAPK1KDM4EMAPTKIT | |
| SCHEMBL8336910 | 0.83 | TRPV1 (1.00) | TRPV1MAPT | |
| SCHEMBL8338303 | 0.82 | TRPV1 (0.63) | TRPV1MAPK1KDM4EMAPTKIT | |
| SCHEMBL14423770 | 0.78 | TRPV1 (0.69) | TRPV1KDM4EMAPTKIT | |
| SCHEMBL13407141 | 0.78 | TRPV1 (0.76) | TRPV1MAPK1KDM4EMAPTKIT | |
| SCHEMBL12230326 | 0.74 | MAPK1 (1.00) | TRPV1MAPK1KDM4EMAPTKIT | |
| SCHEMBL4558228 | 0.74 | EPHX2 (0.91) | TRPV1EPHX2POLB | |
| SCHEMBL4262868 | 0.73 | TRPV1 (0.77) | TRPV1KIT | |
| SCHEMBL2914930 | 0.73 | PDGFRB (0.82) | KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7696207-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2010-04-13 | — | — | US | disclosed |
| US-7696207-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2010-04-13 | — | — | US | disclosed |
| US-20080200472-A1 | Therapeutic agents useful for treating pain | EURO-CELTIQUE S.A. | 2008-08-21 | — | — | US | disclosed |
| US-20080200472-A1 | Therapeutic agents useful for treating pain | EURO-CELTIQUE S.A. | 2008-08-21 | — | — | US | disclosed |
| US-7262194-B2 | Therapeutic agents useful for treating pain | EURO-CELTIQUE S.A. | 2007-08-28 | — | — | US | disclosed |
| US-7262194-B2 | Therapeutic agents useful for treating pain | EURO-CELTIQUE S.A. | 2007-08-28 | — | — | US | disclosed |
| WO-2004011441-A1 | PYRIDAZINYLPIPERAZINE DERIVATIVES FOR TREATING PAIN | EURO-CELTIQUE S.A. (LU) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200472-A1 | Therapeutic agents useful for treating pain | HRH2, OPRL1, TRPV1 | TRPV1 3/4885MAPK1 1619/4885KDM4E 3626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.